Delta Sleep-Inducing Peptide DSIP

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

1. Core Molecular & Quality Specifications

2. Mechanism of Action

1. Sleep Regulation: Enhances delta-wave EEG activity by modulating GABAergic/glutamatergic systems and promoting somatoliberin (GHRH) release, which drives slow-wave sleep. It does not sedate but normalizes sleep architecture, increasing SWS duration by ~35% in animal models.
2. Stress Protection: Inhibits stress-induced corticotropin (ACTH) and cortisol secretion; upregulates antioxidant enzymes (e.g., SOD) to reduce oxidative damage from chronic stress.
3. Endocrine Modulation: Stimulates luteinizing hormone (LH) release (supports testosterone production) and inhibits somatostatin, indirectly boosting growth hormone (GH) secretion.
4. Analgesia & Addiction: Modulates opioid and monoaminergic pathways to reduce pain perception; alleviates alcohol/opioid withdrawal symptoms by stabilizing neurotransmitter balance.

3. Pharmacological Profile

3.1 Key Effects

• Sleep Enhancement: Increases delta-wave activity in neocortex/limbic cortex; improves sleep efficiency without next-day grogginess (unlike benzodiazepines).
• Stress Resilience: Reduces stress-induced hypertension, tachycardia, and metabolic dysfunction in preclinical models.
• Pain Relief: ED₅₀ (rat, i.c.v.) ~10 nmol/kg for inflammatory pain; synergizes with opioids to lower tolerance risk.
• Addiction Support: Mitigates withdrawal symptoms (anxiety, cravings) in alcohol/opioid dependence via hypothalamic-pituitary-adrenal (HPA) axis modulation.

3.2 Pharmacokinetics

• Absorption: Oral bioavailability ~15–20% (resists peptidases); subcutaneous (s.c.) or intranasal administration yields peak plasma levels at 30–60 minutes.
• Half-Life: Systemic t₁/₂ ~60–90 minutes; extended to 2–3 hours in cerebrospinal fluid (CSF).
• Metabolism: Cleaved by aminopeptidases at N-terminal Trp; excreted in urine as di/tripeptide metabolites.

4. Applications

4.1 Research & Preclinical

• Neuroscience: Tool to study sleep-circadian rhythm interaction; model for HPA axis regulation in stress disorders.
• Drug Development: Template for sleep aids with minimal side effects; lead compound for stress-related depression therapeutics.
• Pain Management: Preclinical trials for chronic neuropathic pain (synergizes with NSAIDs/opioids).

4.2 Clinical Investigational

• Sleep Disorders: Phase II trials for insomnia (increases SWS by 20–40% vs. placebo); no tolerance/dependence reported.
• Addiction Medicine: Used off-label to reduce alcohol/opioid withdrawal severity (e.g., anxiety, tremors).
• Palliative Care: Adjuvant for cancer pain (enhances opioid efficacy, reduces side effects).

4.3 Sports & Wellness

• Recovery: Promotes post-exercise muscle repair via GH upregulation (research stage).

5. Synthesis & Quality Control

5.1 Production

• Solid-Phase Peptide Synthesis (SPPS): Fmoc-protected Trp at position 1; coupling of D-Asp and L-Ala via HBTU/HOBt activation.
• Purification: Reverse-phase HPLC (C18 column, 0.1% TFA in acetonitrile/water gradient) to ≥98% purity; lyophilization for stability.

5.2 Quality Testing

• Purity: HPLC (UV 220 nm) + mass spectrometry (ESI-MS) for sequence confirmation.
• Bioactivity: Rabbit EEG delta-wave assay or mouse tail-flick test for analgesic potency.
• Sterility: 0.22 μm filtration for injectable formulations.

6. Safety & Handling

6.1 Hazards

• Toxicity: LD₅₀ (mouse, i.v.) >1 mg/kg; low acute toxicity. Adverse effects at high doses: mild sedation, hypotension, or nausea (reversible).
• Contraindications: Hypersensitivity to peptide components; pregnancy (insufficient data).
• Drug Interactions: May potentiate sedatives/opioids—reduce doses by 30–50% when co-administered.

6.2 Handling Guidelines

• PPE: Lab coat, nitrile gloves, safety goggles (powder inhalation risk).
• Reconstitution: Dissolve 1 mg in 1 mL sterile water/0.9% NaCl; use within 48 hours at 2–8°C.
• Disposal: Incinerate unused material per biomedical waste protocols.